The central bank has launched two measures at the same time! The reserve requirement ratio is reduced by 0.5 percentage points, and the 7-day reverse repurchase operation interest rate is lowered by 20 basis points.
Starting from September 27, 2024, the reserve requirement ratio for financial institutions is reduced by 0.5 percentage points. After this reduction, the weighted average reserve requirement ratio for financial institutions is approximately 6.6%.
From January to July, the cumulative scale of the national retail pharmacy market reached 299.1 billion yuan, a year-on-year decrease of 3.3%.
The listing of Dapagliflozin Metformin ER tablets will further intensify the competition in the domestic antidiabetic drug market.
Spdr Index Shares Funds Spdr S&P Emerging Mkts Dividend Etf To Go Ex-Dividend On September 23rd, 2024 With 0.58758 USD Dividend Per Share
September 20th (Eastern Time) - $Spdr Index Shares Funds Spdr S&P Emerging Mkts Dividend Etf(EDIV.US)$ is trading ex-dividend on September 23rd, 2024.Shareholders of record on September 23rd, 2024
Southeast Asian stock markets are strong! Global capital continues to pour in, how to seize this wave of market trends?
After experiencing the 'Black Monday' on August 5th, major stock indices in the Asia-Pacific region rebounded significantly, with Southeast Asian stock markets performing particularly well. Southeast Asian stock markets have consolidated their position as the most favored investment symbol for fund managers during the shifting policy of the Federal Reserve.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
A storm is quietly brewing, and emerging markets are starting a frenzy of bond issuance.
Borrowers in developing countries are strengthening their defenses against fluctuations.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
①The growth rate of total sales revenue of retail pharmacies has slowed down, and the competition continues to intensify. In the first half of this year, major leading chain drugstores found it difficult to increase revenue and profit; ②In the future, the focus of pharmacy competition will shift to product extension and services. According to Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all terminals is expected to decrease to 4.9% in 2024, compared to the decline in 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
① At the 2024 New Investment Conference hosted by Forrester Sullivan, the issue of going global was highly favored by the participants. ② There is a new trend in the global expansion of innovative drugs in our country, such as the number of BDs going global surpassing License-in for the first time in 2023. ③ Some experts at the conference proposed a rational view and called for the need to strengthen internal capabilities, not just rely on enthusiasm.
One chart to understand | The list of bull and bear stocks in the US stock market in August is out! Performance of quality stocks is impressive, with the US version of 'Huabei' Affirm soaring nearly 50%, and Mediterranean dining brand CAVA rising more tha
This month, the three major stock indexes in the US rose and fell differently. The Dow Jones index reached a new high, closing up 1.21%, the S&P 500 index closed up 1.26%, and the Nasdaq Composite Index closed down 0.47%.
Shares of Banking Companies Are Trading Higher Amid Overall Market Strength Following Fed Chair Powell's Comments About the Economy and Future Rate Cuts.
Goldman Sachs Maintains Buy on Bank Bradesco, Raises Price Target to $3.2
Bank Bradesco Analyst Ratings
Financial Stocks Eke Out Small Gain in Exceptionally Volatile Week
Over 400 pharmaceuticals selected! The preliminary list of the 2024 National Drug Reimbursement List has been published. Experts predict that the threshold for innovative drugs may be lowered.
This year, 440 pharmaceuticals were preliminarily reviewed and included in the drug list for national medical insurance negotiations, with 196 and 244 pharmaceuticals inside and outside the catalog respectively. Many of the applied drugs are innovative drugs that will be launched in June. Several of them have preemptively reduced their prices to increase the probability of successful negotiations. Based on supportive policies, experts predict that the threshold for access to innovative drugs may be lowered this year, and the number of them may increase.
The list of initial review of the national dialogue in 2024 has been announced! Many heavyweight innovative drugs are listed, and almost all CAR-T varieties are gathered. Will there be breakthroughs? | Industry observation
This evening, the National Medical Insurance Bureau announced the list of drugs that passed the preliminary review of the national negotiations this year. The bureau received 626 applications from enterprises, and 440 drugs passed the preliminary review. Several heavy-weight innovative drugs have been approved by the wire or reduced in price, which is considered by the industry as the most important channel for the commercial realization of innovative drugs through medical insurance eligibility. Almost all types of domestic CAR-T are gathered, and experts predict that there may be breakthroughs this year.
Bando Bradesco Shares Are Trading Higher. The Company Reported Q2 Financial Results.
Bank Bradesco Q2 2024 GAAP EPS $0.08, Inline, Sales $3.279B Miss $5.431B Estimate
Midday Snapshot | Hong Kong stocks rise and fall, Hang Seng index falls nearly 1%; Macau casino stocks rise against the trend, MGM China up more than 5%.
Cryptocurrency spot ETFs plummeted, with Bosera Ethereum, Huaxia Ethereum, and Jiashi Ethereum falling by more than 27%, while Jiashi Bitcoin and Bosera Bitcoin fell nearly 16%.
These listed companies have been "crossing the threshold" since July! Institutions conducted group research on csi sws health care index stocks, and here is a list of stocks with the highest number of institutional receptions.
① List of listed companies that have received visits from over 160 institutions since July (see attached figure). Montage Technology, Zhejiang Crystal-Optech, and Espressif Systems are among the top three. ② In the medical and pharmaceutical industry, Lianyi Medical, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., China Resources Boya Bio-pharmaceutical Group, Maiwei Biology-U, and Zhejiang Jolly Pharmaceutical are also "listed".
Banco Bradesco Goes Ex Dividend Monday